0
0
New Delhi, India – April 18, 2025: Indian pharmaceutical companies are strategically expanding their presence in the rapidly growing US oncology generics market, a sector now valued at $145 billion and demonstrating a robust 11% annual growth rate, according to a recent industry report.
This push comes as several Indian drug manufacturers secure crucial approvals from the US Food and Drug Administration (FDA) for generic cancer medications. The trend highlights an increasing capability within the Indian pharma industry to develop and market complex generics and biosimilars, moving beyond basic formulations. With cancer treatments representing a major global growth area, Indian firms are leveraging their cost-effective manufacturing base, technical prowess, and favourable regulatory outcomes to carve out a significant share.
“This represents a shift in India’s pharma sector from basic generics to complex formulations showcasing its evolving capabilities,” commented an industry expert familiar with the developments.
This ambition is supported by strong foreign investment inflows. India’s pharmaceutical and medical devices sector attracted Rs 11,888 crore in foreign direct investment (FDI) between April and December 2024. Furthermore, in the fiscal year 2025, approvals were granted for 13 brownfield projects amounting to Rs 7,246.4 crore, bringing the total FDI for the period considered to Rs 19,134.4 crore.
A key catalyst for this growth trajectory is the Indian government’s Production Linked Incentive (PLI) Scheme for Pharmaceuticals, launched in 2021 with an initial outlay of Rs 15,000 crore. The scheme specifically targets the domestic manufacturing of high-value products, including complex generics, biopharmaceuticals, and crucially, anti-cancer drugs. Its objectives are twofold: to decrease reliance on imported active pharmaceutical ingredients (APIs) and intermediates, and to significantly boost exports.
The PLI scheme has already shown promising results, exceeding its initial investment targets. By the end of 2024, actual investments under the scheme reached Rs 4,253.92 crore, surpassing the committed investment of Rs 3,938.57 crore. Noteworthy projects supported by the scheme include the establishment of a Penicillin G manufacturing unit in Andhra Pradesh and a Clavulanic Acid facility in Himachal Pradesh. These initiatives are expected to drastically cut import costs for these key starting materials and enhance India’s self-sufficiency and global competitiveness in pharmaceuticals.
Disclaimer: This news article is based on information provided from an external source dated April 18. It summarizes key findings, and while compiled with care, readers should refer to original source materials and official reports for comprehensive details and context.
